Masahiro Kizaki
Overview
Explore the profile of Masahiro Kizaki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
166
Citations
1553
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Katagiri S, Akahane D, Takeyama K, Sato N, Takayama N, Ando J, et al.
Ann Hematol
. 2025 Mar;
PMID: 40059232
In most cases of anaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK + ALCL), long-term survival is achieved using CHOP therapy. However, some cases have a poor prognosis. Here, we...
2.
Naganuma K, Takahashi Y, Anan T, Kizaki M, Momose S, Higashi M, et al.
J Clin Exp Hematop
. 2024 Jul;
64(3):177-182.
PMID: 39085131
High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (HDC/ASCT) has been useful in relapsed or refractory classic Hodgkin lymphoma (RRcHL). Furthermore, a ranimustine, cytarabine, etoposide, and cyclophosphamide (MCVAC) conditioning...
3.
Shibayama H, Itagaki M, Handa H, Yokoyama A, Saito A, Kosugi S, et al.
Int J Hematol
. 2024 Mar;
119(6):707-721.
PMID: 38548963
The emergence of novel drugs has significantly improved outcomes of patients with plasma cell neoplasms (PCN). The Japanese Society of Hematology conducted a prospective observational study in newly diagnosed PCN...
4.
Goto H, Ito S, Kizaki M, Yamaguchi M, Fukuhara N, Kato K, et al.
Int J Clin Oncol
. 2023 Dec;
29(2):232-240.
PMID: 38157190
Background: Despite high response rates to initial therapy, most patients with mantle cell lymphoma (MCL) experience relapsed or refractory (R/R) disease. Here, we report the efficacy, safety, and pharmacokinetics of...
5.
Mitani K, Lee J, Jang J, Tomiyama Y, Miyazaki K, Nagafuji K, et al.
Blood Adv
. 2023 Dec;
8(6):1415-1419.
PMID: 38134300
No abstract available.
6.
Sawada K, Momose S, Iijima Y, Takahashi T, Kaneko T, Yamamoto W, et al.
J Clin Exp Hematop
. 2023 May;
63(2):90-98.
PMID: 37245972
Epstein-Barr virus-positive mucocutaneous ulcer (EBVMCU) is a newly recognized disease entity characterized by EBV-positive atypical B-cell proliferation. EBVMCU is a localized self-limited disease that affects mucosa and skin, especially the...
7.
Tokuhira M, Kimura Y, Tabayashi T, Watanabe N, Tsuchiya S, Takaku T, et al.
Int J Hematol
. 2023 May;
118(2):210-220.
PMID: 37129800
ABL1-tyrosine kinase inhibitors (TKIs) are an established treatment choice for patients with chronic myeloid leukemia in the chronic phase (CML-CP). However, effects of TKI dose modification have not been well...
8.
Tsuchiya S, Takaku T, Watanabe N, Iriyama N, Kimura Y, Iwanaga E, et al.
Intern Med
. 2023 Apr;
62(22):3299-3303.
PMID: 37005261
Objective Pleural effusion (PE) is a common adverse event that occurs during dasatinib therapy for chronic myeloid leukemia (CML). However, the pathomechanism of PE and appropriate management of Asian patients...
9.
Matsunaga T, Naganuma K, Tabayashi T, Kawada T, Sakata N, Takahashi Y, et al.
Rinsho Ketsueki
. 2023 Jan;
63(12):1643-1647.
PMID: 36653137
A 62-year-old woman was presented at our hospital with visual disturbance. An ocular examination revealed bilateral Roth spots. Laboratory data revealed leukocytosis (236,200 µl) with an excess blast (11%). Physical...
10.
Naganuma K, Tabayashi T, Kawada T, Sakata N, Takahashi Y, Kimura Y, et al.
Rinsho Ketsueki
. 2022 Dec;
63(11):1525-1529.
PMID: 36476792
A 76-year-old woman with leukocytosis and thrombocytopenia was admitted to our hospital. A bone marrow examination showed a composition of 82.0% blasts, i.e., positive for TdT, CD10, CD19, CD34, and...